Jardiance® (empagliflozin) – Expanded indication
February 24, 2022 - The FDA announced the approval of Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin), to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure (HHF) in adults with heart failure.
Download PDF
